Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

GNMX vs. PRHSX: which is better?

Bottom line

GNMX vs PRHSX: the short answer

GNMX (Corgi Genomics & Precision Medicine ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.

Updated Nov 19, 2026

GNMX vs PRHSX side by side

GNMXPRHSX
TypeETFMutual fund
Fund familyCorgi Genomics & Precision MedicineT. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio—0.83%
Annual cost per $10k—$83
10-yr cost on $10k (prospectus)—$1,025
Max front loadNone—
12b-1 fee——
1-yr return—+17.7%
5-yr return (annualized)—+4.2%
10-yr return (annualized)—+9.1%
Best quarter—+23.5%
Worst quarter—−15.8%
Net assets (fund)—$11.9B
Number of holdings—279
Portfolio turnover—62%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

GNMX and PRHSX share none of their top holdings.

GNMX top 10

    PRHSX top 10

    1. Eli Lilly & Co — 14.28%
    2. Johnson & Johnson — 6.63%
    3. Unitedhealth Group Inc — 5.99%
    4. Abbvie Inc — 5.10%
    5. Merck & Co. Inc. — 4.01%
    6. Gilead Sciences Inc — 2.82%
    7. Thermo Fisher Scientific Inc — 2.52%
    8. Vertex Pharmaceuticals Inc — 2.28%
    9. Bristol-myers Squibb Co — 2.11%
    10. Abbott Laboratories — 1.89%

    FAQ

    What is the difference between GNMX and PRHSX?
    GNMX (Corgi Genomics & Precision Medicine ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.
    Should I own both GNMX and PRHSX?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.